Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
FOLD logo FOLD
Upturn stock ratingUpturn stock rating
FOLD logo

Amicus Therapeutics Inc (FOLD)

Upturn stock ratingUpturn stock rating
$5.73
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/30/2025: FOLD (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

12 Analysts rated it

Well-followed company, solid analyst reports, reliable data for confident investing.

1 Year Target Price $15.82

1 Year Target Price $15.82

Analysts Price Target For last 52 week
$15.82Target price
Low$5.51
Current$5.73
high$12.65

Analysis of Past Performance

Type Stock
Historic Profit -28.92%
Avg. Invested days 28
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/30/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 1.83B USD
Price to earnings Ratio -
1Y Target Price 15.82
Price to earnings Ratio -
1Y Target Price 15.82
Volume (30-day avg) 12
Beta 0.53
52 Weeks Range 5.51 - 12.65
Updated Date 06/29/2025
52 Weeks Range 5.51 - 12.65
Updated Date 06/29/2025
Dividends yield (FY) -
Basic EPS (TTM) -0.09

Analyzing Revenue: Products, Geography and Growth

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -5.41%
Operating Margin (TTM) -6.35%

Management Effectiveness

Return on Assets (TTM) 3.95%
Return on Equity (TTM) -18.12%

Valuation

Trailing PE -
Forward PE 49.02
Enterprise Value 2018923735
Price to Sales(TTM) 3.36
Enterprise Value 2018923735
Price to Sales(TTM) 3.36
Enterprise Value to Revenue 3.72
Enterprise Value to EBITDA 37.65
Shares Outstanding 307931008
Shares Floating 263933805
Shares Outstanding 307931008
Shares Floating 263933805
Percent Insiders 0.75
Percent Institutions 102.83

Analyst Ratings

Rating 4
Target Price 15.82
Buy 1
Strong Buy 8
Buy 1
Strong Buy 8
Hold 3
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Amicus Therapeutics Inc

stock logo

Company Overview

overview logo History and Background

Amicus Therapeutics, founded in 2002, is a biotechnology company focused on developing therapies for rare genetic diseases. It has evolved from a research-focused organization to a commercial enterprise with approved products.

business area logo Core Business Areas

  • Rare Disease Therapeutics: Amicus develops and commercializes therapies for rare genetic diseases, focusing on protein folding and enzyme replacement therapies.

leadership logo Leadership and Structure

John F. Crowley serves as Chairman and CEO. The company has a typical corporate structure with functional departments such as R&D, Commercial, and Finance.

Top Products and Market Share

overview logo Key Offerings

  • Galafold (migalastat): Galafold is an oral chaperone therapy approved for Fabry disease patients with amenable mutations. It competes with enzyme replacement therapies. Global Galafold revenue in 2023 was approximately $417.3 million. Competitors: Sanofi (ENZYME), Takeda (TAK)
  • Pombiliti + Opfolda: Pombiliti + Opfolda is a two-component therapy for late-onset Pompe disease. Competitors: Sanofi (ENZYME). First full year sales expected in 2024, analysts are expecting strong sales.

Market Dynamics

industry overview logo Industry Overview

The rare disease therapeutics market is growing rapidly due to increased awareness, orphan drug designations, and advancements in gene therapy and precision medicine.

Positioning

Amicus is a key player in the rare disease space, specializing in Fabry and Pompe diseases. Its competitive advantage lies in its oral chaperone therapy for Fabry and innovative two-component therapy for Pompe, offering alternatives to traditional enzyme replacement therapies.

Total Addressable Market (TAM)

The rare disease market is estimated to be hundreds of billions of dollars globally. Amicus is positioned to capture a significant share of the Fabry and Pompe disease segments, as well as future pipeline products.

Upturn SWOT Analysis

Strengths

  • Approved and marketed products (Galafold, Pombiliti + Opfolda)
  • Strong pipeline of rare disease therapies
  • Focus on protein folding technology
  • Experienced management team
  • Orphan drug designations

Weaknesses

  • Reliance on a limited number of products
  • High R&D expenses
  • Commercialization challenges in certain markets
  • Patent protection vulnerabilities

Opportunities

  • Expanding indications for existing products
  • Acquiring or licensing new rare disease assets
  • Entering new geographic markets
  • Developing gene therapy programs

Threats

  • Competition from larger pharmaceutical companies
  • Pricing pressures and reimbursement challenges
  • Clinical trial failures
  • Regulatory hurdles
  • Generic erosion of Galafold

Competitors and Market Share

competitor logo Key Competitors

  • SNY
  • TAK

Competitive Landscape

Amicus's oral chaperone therapy provides a unique advantage in the Fabry disease market compared to enzyme replacement therapies. However, competitors like Sanofi and Takeda have larger sales/marketing force.

Major Acquisitions

Callidus Biopharma

  • Year: 2017
  • Acquisition Price (USD millions): 130
  • Strategic Rationale: Expanded pipeline with Pompe disease and other lysosomal storage disorder programs.

Growth Trajectory and Initiatives

Historical Growth: Amicus has experienced significant revenue growth since the launch of Galafold.

Future Projections: Analysts project continued revenue growth, driven by Galafold and launch of Pombiliti + Opfolda, and potential pipeline progress. Profitability is expected within the next few years.

Recent Initiatives: Recent initiatives include expanding the Galafold label, commercializing Pombiliti + Opfolda, and advancing its gene therapy programs.

Summary

Amicus Therapeutics is a growing biopharmaceutical company focused on rare diseases. Galafold's strong sales, coupled with the recent launch of Pombiliti + Opfolda are helping. High R&D costs continue to weigh on profitability. The company will need to successfully navigate competition and execute its pipeline strategy to maintain its growth trajectory.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Amicus Therapeutics Inc. Investor Relations
  • SEC Filings
  • Analyst Reports
  • Company Press Releases

Disclaimers:

The information provided is for informational purposes only and should not be considered investment advice. Market share estimates are based on available data and may not be precise. Future results are subject to various risks and uncertainties.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Amicus Therapeutics Inc

Exchange NASDAQ
Headquaters Princeton, NJ, United States
IPO Launch date 2007-05-31
CEO, President & Director Mr. Bradley L. Campbell M.B.A.
Sector Healthcare
Industry Biotechnology
Full time employees 499
Full time employees 499

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally. The company's commercial product and product candidates consist of Galafold, an orally administered monotherapy for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, a novel two-component treatment program for adults living with late-onset Pompe disease. It has collaboration and license agreement with GlaxoSmithKline to develop and commercialize Galafold. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.